The biotech sector is seeing rapid growth due to two new bird flu infections, causing shares in companies like Moderna and BioNTech to rise significantly. Notably, BioNTech has revealed advancements in Cancer Immunotherapy and intends to launch ten critical cancer studies in 2024. In the Covid-19 vaccine patent dispute, Moderna has come out on top against Pfizer-BioNTech in Europe. Even as this legal battle unfolds, collaboration is seen between Medigene & BioNTech in T Cell Receptor Immunotherapy. Yet, trouble brews as litigation over Covid-19 vaccine technology ensues against Pfizer and BioNTech. BioNTech is also grappling with a disturbing financial outlook, a Covid royalty dispute, and a net loss of €315.1m in Q1 2024. Other notable events include an extension of the TCR immunotherapy collaboration with Medigene, a strategic worldwide license agreement with MediLink Therapeutics, and a new mRNA vaccine manufacturing site in Rwanda. Despite setbacks such as earnings misses and inventory write-downs, BioNTech continues to innovate, focusing on ADCs and CAR-Ts to drive future growth.
BIONTECH News Analytics from Mon, 07 Aug 2023 07:00:00 GMT to Thu, 23 May 2024 15:08:53 GMT -
Rating 2
- Innovation 6
- Information 5
- Rumor -5
